Cited 20 times in
Liposomal irinotecan plus fluorouracil/leucovorin versus FOLFIRINOX as the second-line chemotherapy for patients with metastatic pancreatic cancer: a multicenter retrospective study of the Korean Cancer Study Group (KCSG)
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 이충근 | - |
dc.contributor.author | 최혜진 | - |
dc.date.accessioned | 2021-04-29T17:30:49Z | - |
dc.date.available | 2021-04-29T17:30:49Z | - |
dc.date.issued | 2021-02 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/182379 | - |
dc.description.abstract | Background: There is no clear consensus on the recommended second-line treatment for patients with metastatic pancreatic cancer who have disease progression following gemcitabine-based therapy. We retrospectively evaluated the clinical outcomes of liposomal irinotecan (nal-IRI) plus fluorouracil/leucovorin (FL) and FOLFIRINOX (fluorouracil, leucovorin, irinotecan, and oxaliplatin) in patients who had failed on the first-line gemcitabine-based therapy. Patients and methods: From January 2015 to August 2019, 378 patients with MPC who had received nal-IRI/FL (n = 104) or FOLFIRINOX (n = 274) as second-line treatment across 11 institutions were included in this retrospective study. Results: There were no significant differences in baseline characteristics between groups, except age and first-line regimens. With a median follow-up of 6 months, the median progression-free survival (PFS) was 3.7 months with nal-IRI/FL versus 4.6 months with FOLFIRINOX (P = 0.44). Median overall survival (OS) was 7.7 months with nal-IRI/FL versus 9.7 months with FOLFRINOX (P = 0.13). There was no significant difference in PFS and OS between the two regimens in the univariate and multivariate analyses. The subgroup analysis revealed that younger age (<70 years) was associated with better OS with FOLFIRINOX. In contrast, older age (≥70 years) was associated with better survival outcomes with nal-IRI/FL. Adverse events were manageable with both regimens; however, the incidence of grade 3 or higher neutropenia and peripheral neuropathy was higher in patients treated with FOLFIRINOX than with nal-IRI/FL. Conclusions: Second-line nal-IRI/FL and FOLFIRINOX showed similar effectiveness outcomes after progression following first-line gemcitabine-based therapy. Age could be the determining factor for choosing the appropriate second-line therapy. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | BMJ | - |
dc.relation.isPartOf | ESMO OPEN | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Liposomal irinotecan plus fluorouracil/leucovorin versus FOLFIRINOX as the second-line chemotherapy for patients with metastatic pancreatic cancer: a multicenter retrospective study of the Korean Cancer Study Group (KCSG) | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | H S Park | - |
dc.contributor.googleauthor | B Kang | - |
dc.contributor.googleauthor | H J Chon | - |
dc.contributor.googleauthor | H-S Im | - |
dc.contributor.googleauthor | C-K Lee | - |
dc.contributor.googleauthor | I Kim | - |
dc.contributor.googleauthor | M J Kang | - |
dc.contributor.googleauthor | J E Hwang | - |
dc.contributor.googleauthor | W K Bae | - |
dc.contributor.googleauthor | J Cheon | - |
dc.contributor.googleauthor | J O Park | - |
dc.contributor.googleauthor | J Y Hong | - |
dc.contributor.googleauthor | J H Kang | - |
dc.contributor.googleauthor | J H Kim | - |
dc.contributor.googleauthor | S H Lim | - |
dc.contributor.googleauthor | J W Kim | - |
dc.contributor.googleauthor | J-W Kim | - |
dc.contributor.googleauthor | C Yoo | - |
dc.contributor.googleauthor | H J Choi | - |
dc.identifier.doi | 10.1016/j.esmoop.2021.100049 | - |
dc.contributor.localId | A03259 | - |
dc.contributor.localId | A04219 | - |
dc.relation.journalcode | J03799 | - |
dc.identifier.eissn | 2059-7029 | - |
dc.identifier.pmid | 33578192 | - |
dc.subject.keyword | FOLFIRINOX | - |
dc.subject.keyword | liposomal irinotecan | - |
dc.subject.keyword | pancreatic cancer | - |
dc.subject.keyword | second-line treatment | - |
dc.contributor.alternativeName | Lee, Choong-kun | - |
dc.contributor.affiliatedAuthor | 이충근 | - |
dc.contributor.affiliatedAuthor | 최혜진 | - |
dc.citation.volume | 6 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 100049 | - |
dc.identifier.bibliographicCitation | ESMO OPEN, Vol.6(2) : 100049, 2021-02 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.